Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. [electronic resource]
- The Journal of biological chemistry Dec 2003
- 50259-72 p. digital
Publication Type: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
0021-9258
10.1074/jbc.M307444200 doi
Animals Apoptosis Blotting, Western Bone Resorption Calcium--metabolism Carrier Proteins--metabolism Cells, Cultured Core Binding Factor Alpha 1 Subunit Culture Media, Conditioned--pharmacology Cyclic AMP Response Element-Binding Protein--metabolism Cyclic AMP-Dependent Protein Kinases--metabolism Cysteine Endopeptidases--metabolism Dactinomycin--pharmacology Female HeLa Cells Humans Kinetics Membrane Glycoproteins--metabolism Mice Mice, Inbred C57BL Models, Biological Models, Genetic Multienzyme Complexes--metabolism Neoplasm Proteins Osteoblasts--metabolism Parathyroid Hormone--metabolism Phosphorylation Proteasome Endopeptidase Complex Proto-Oncogene Proteins c-bcl-2--metabolism RANK Ligand RNA--metabolism RNA, Messenger--metabolism Receptor Activator of Nuclear Factor-kappa B Signal Transduction Time Factors Transcription Factors--metabolism Transcription, Genetic bcl-Associated Death Protein